Cardiol Therapeutics (TSE:CRDL) has released an update.
Cardiol Therapeutics, a clinical-stage life sciences company, has announced the pricing of its public offering of 8,437,500 Common Shares at $1.60 each, aiming to raise $13.5 million. The funds are intended to further the clinical development of CardiolRx for recurrent pericarditis and cover general expenses. The offering is set to close on October 10, 2024, with Canaccord Genuity acting as the sole bookrunner.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
